



Factor Therapeutics Limited Extraordinary General Meeting Chairman's Address

Brisbane (Australia) 9 September 2021: Factor Therapeutics Limited (ASX:FTT) ("Factor" or "the Company") is pleased to provide the Chairman's Address to the Extraordinary General Meeting of Shareholders being held today from 1.00pm (AEST) (EGM).

Due to the developments in relation to the COVID-19 situation, the EGM is being held as a virtual meeting. The virtual AGM can be accessed at <https://agmlive.link/FTTEGM21>.

CHAIRMAN'S ADDRESS

As Shareholders are aware, Factor is seeking to acquire PowerLime, Inc., an unlisted company with a prospective high calcium limestone project located in Georgia, USA. The acquisition of PowerLime is the subject of the majority of Resolutions being put to Shareholders today.

In addition to the acquisition, a number of Resolutions relate to the Offer to raise \$4M through the issue of new shares in the Company. This Offer is associated with the Company's application to relist on the ASX. The Board has instructed the Lead Manager to set aside \$800,000 of the Offer for allocation to existing FTT Shareholders.

The change in focus to resources involves a restructure of the Company and the Board.

Upon re-listing, we will welcome new Directors Dominic Allen, a finance professional with a long track record in the management and operations of natural resources organisations, and Anastasios Arima, the founder of multiple mining and natural resources companies with a successful record of identifying opportunities, raising finance and building strong teams.

Together the Board and management of the renamed Dominion Minerals Limited bring expertise in the resources sector and a track record of adding value for shareholders, with Piedmont Lithium (ASX:PLL) and Hyperion Metals (ASX:HYM) being recent examples.

The initial priority of the Board and management is to advance exploration work at the PowerLime project, on a pathway targeting delivery of a JORC-compliant mineral resource estimate by the end of this year, 2021.

I will take this opportunity to thank current Factor Directors, John Michailidis and Melanie Farris, who will retire from the Board, and in Melanie's case, also as the long-standing Company Secretary, having overseen the completion of the PowerLime transaction through to re-listing.

John and Melanie have been involved with the Company for many years and have always demonstrated a strong commitment to Shareholders. Both are involved in exciting and leading opportunities in the life sciences space. We wish John and Melanie the very best and look forward to continuing to work with them in these last weeks until re-listing as anticipated in mid-October.



The Board has been very appreciative of the support from Shareholders during the Company's suspension, while working towards the obvious objective to re-list as soon as possible. The Board will be working to create Shareholder value and to provide regular updates.

An early "update" relates to the issue of a replacement prospectus lodged with ASIC today, the 9th of September. This follows changes requested by ASIC to the Original Prospectus dated 27 August 2021, for the amendment of some details, including aspects of the description and assessment of the high calcium limestone project in south Georgia.

I encourage shareholders to review the Important Notices section of the Replacement Prospectus – which is available on the ASX - which sets out the material differences between the Original Prospectus and the Replacement Prospectus.

Factor is appreciative of the cooperation of the ASX and ASIC in expediting the process to allow modification to the Prospectus without causing delay to the intended timeline.

-ENDS-

For further information:

Dr David Brookes

Chairman, Factor Therapeutics Limited

via m.farris@factor-therapeutics.com